- Home
- HIMS
as 01-23-2025 3:37pm EST
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 6.6B | IPO Year: | N/A |
| Target Price: | $26.21 | AVG Volume (30 days): | 10.1M |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.51 - $35.02 | Next Earning Date: | 02-24-2025 |
| Revenue: | $1,241,994,000 | Revenue Growth: | 56.70% |
| Revenue Growth (this year): | 71.44% | Revenue Growth (next year): | 39.33% |
Stock Insider Trading Activity of Hims & Hers Health Inc. (HIMS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dudum Andrew | HIMS | Chief Executive Officer | Jan 16 '25 | Sell | $27.16 | 83,994 | $2,271,413.73 | 475,330 | |
| Okupe Oluyemi | HIMS | Chief Financial Officer | Jan 13 '25 | Sell | $24.51 | 11,581 | $283,083.26 | 120,465 | |
| Boughton Soleil | HIMS | Chief Legal Officer | Jan 6 '25 | Sell | $27.86 | 268,932 | $7,463,195.04 | 169,803 | |
| Okupe Oluyemi | HIMS | Chief Financial Officer | Jan 2 '25 | Sell | $24.68 | 11,581 | $285,783.63 | 120,465 | |
| Chi Michael | HIMS | Chief Commercial Officer | Jan 2 '25 | Sell | $24.62 | 2,055 | $50,594.10 | 193,601 | |
| Okupe Oluyemi | HIMS | Chief Financial Officer | Dec 26 '24 | Sell | $29.98 | 4,213 | $126,317.96 | 120,465 | |
| Chi Michael | HIMS | Chief Commercial Officer | Dec 24 '24 | Sell | $27.97 | 17,303 | $483,964.91 | 193,601 | |
| Okupe Oluyemi | HIMS | Chief Financial Officer | Dec 20 '24 | Sell | $25.76 | 18,959 | $488,530.89 | 120,465 | |
| Chi Michael | HIMS | Chief Commercial Officer | Dec 19 '24 | Sell | $26.00 | 7,500 | $195,000.00 | 193,601 | |
| Dudum Andrew | HIMS | Chief Executive Officer | Dec 13 '24 | Sell | $30.01 | 409,814 | $12,488,567.87 | 475,330 |
Latest Hims & Hers Health Inc. News
HIMS Breaking Stock News: Dive into HIMS Ticker-Specific Updates for Smart Investing
Argus Research
2 days ago
HIMS: Rating decreased to a HOLD
Simply Wall St.
8 days ago
Investors in Hims & Hers Health (NYSE:HIMS) have seen enviable returns of 440% over the past three years
Argus Research
9 days ago
HIMS: Rating increased to a BUY
Simply Wall St.
a month ago
3 US Growth Companies With Insider Ownership Up To 17%
Simply Wall St.
a month ago
Should You Investigate Hims & Hers Health, Inc. (NYSE:HIMS) At US$28.15?
Argus Research
a month ago
HIMS: Lowering target price to $29.00
Investor's Business Daily
a month ago
IBD 50's Hims & Hers Tumbles After FDA Pulls Lilly's Weight-Loss Drug From Shortage List
Yahoo Finance Video
a month ago
Eli Lily GLP-1 shortage ends, FDA says: Hims & Hers stock falls
Compare HIMS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HIMS Hims & Hers Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.